GLP-1 Market
LLY $1279.14 ▲ +0.4% NVO $39.13 ▲ +0.2% PFE $29.79 ▼ -0.8% VKTX $24.21 ▼ -0.8% KLRA $12.77 ▼ -0.6% GPCR $21.10 ▼ -0.4% RHHBY $59.98 ▼ -1.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Infigratinib

Company
QED Therapeutics, a BridgeBio company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 27, 2026

Find a Clinical Trial Near Me

See recruiting studies for Infigratinib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07169279

    Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

    Not yet reported QED Therapeutics, a BridgeBio company 77 participants Est. completion 2032-03 12 sites Stand-alone
    Other conditions: Achondroplasia
    View official trial listing →
  • Completed NCT NCT01004224

    A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

    Not yet reported Novartis Pharmaceuticals 208 participants Est. completion 2018-10-08 50 sites
    Other conditions: Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
    View official trial listing →
  • Completed NCT NCT01697605

    A Phase I Study of Oral BGJ398 in Asian Patients

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2019-02-07 8 sites
    Other conditions: Tumor With Alterations of the FGF-R
    View official trial listing →
  • Completed NCT NCT01928459

    Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

    Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2016-08 22 sites
    Other conditions: Advanced Solid Tumors, Metastatic Solid Tumors
    View official trial listing →
  • Completed NCT NCT01975701

    A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

    Not yet reported Novartis Pharmaceuticals 26 participants Est. completion 2018-10-03 17 sites
    Other conditions: Recurrent Glioblastoma or Other Glioma Subtypes
    View official trial listing →
  • Terminated NCT NCT02150967

    A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

    Not yet reported QED Therapeutics, a BridgeBio company 143 participants Est. completion 2022-02-07 37 sites Stand-alone
    Other conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
    View official trial listing →
  • Completed NCT NCT02159066

    LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

    Not yet reported Pfizer 158 participants Est. completion 2023-01-10 32 sites
    Other conditions: Melanoma
    View official trial listing →
  • Terminated NCT NCT02160041

    BGJ398 for Patients With Tumors With FGFR Genetic Alterations

    Not yet reported Novartis Pharmaceuticals 84 participants Est. completion 2018-04-30 56 sites
    Other conditions: Solid Tumor, Hematologic Malignancies
    View official trial listing →
  • Completed NCT NCT02257541

    BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 16 participants Est. completion 2019-03-25 7 sites
    Other conditions: Advanced Gastrointestinal Stromal Tumor (GIST)
    View official trial listing →
  • Withdrawn NCT NCT02312804

    Ph Ib/BGJ398/Cervix and Other Solid Tumors

    Not yet reported The University of Texas Health Science Center at San Antonio Est. completion 2015-01
    Other conditions: Cancer of Cervix, Tumors
    View official trial listing →
  • Withdrawn NCT NCT02575508

    Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

    Not yet reported, Not yet reported Roswell Park Cancer Institute 1 site
    Other conditions: Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
    View official trial listing →
  • Completed NCT NCT02657486

    BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

    Not yet reported Memorial Sloan Kettering Cancer Center 4 participants Est. completion 2026-02-04 1 site
    Other conditions: Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
    View official trial listing →
  • Terminated NCT NCT02706691

    BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

    Not yet reported University of Chicago 1 participants Est. completion 2019-02-11 1 site Stand-alone
    Other conditions: FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT03510455

    BGJ398 for the Treatment of Tumor-Induced Osteomalacia

    Not yet reported National Institute of Dental and Craniofacial Research (NIDCR) 4 participants Est. completion 2020-05-04 1 site
    Other conditions: Tumor-Induced Osteomalacia, Oncogenic Osteomalacia
    View official trial listing →
  • Terminated NCT NCT03773302

    Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

    Not yet reported QED Therapeutics, a BridgeBio company 48 participants Est. completion 2023-03-02 116 sites Stand-alone
    Other conditions: Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
    View official trial listing →
  • Terminated NCT NCT04197986

    Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

    Not yet reported QED Therapeutics, a BridgeBio company 39 participants Est. completion 2023-02-28 143 sites Stand-alone
    Other conditions: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
    View official trial listing →
  • Terminated NCT NCT04228042

    Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2024-04-17 1 site Stand-alone
    Other conditions: Renal Pelvis and Ureter Urothelial Carcinoma
    View official trial listing →
  • Completed NCT NCT04233567

    Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

    Not yet reported Sameek Roychowdhury 17 participants Est. completion 2024-12-12 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Cholangiocarcinoma, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT04265651

    Study of Infigratinib in Children With Achondroplasia

    Not yet reported QED Therapeutics, a BridgeBio company 84 participants Est. completion 2024-10-21 19 sites Stand-alone
    Other conditions: Achondroplasia
    View official trial listing →
  • Terminated NCT NCT04424966

    Infigratinib in Recurrent High-Grade Glioma Patients

    Not yet reported Nader Sanai 7 participants Est. completion 2024-02-19 3 sites Stand-alone
    Other conditions: Glioma, Glioblastoma, GBM
    View official trial listing →
  • Terminated NCT NCT04504331

    Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

    Not yet reported Jennifer Lee Caswell-Jin 4 participants Est. completion 2021-10-22 1 site Stand-alone
    Other conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04972253

    Phase I BLASST-3 Trial

    Not yet reported Guru P. Sonpavde Est. completion 2023-12 Stand-alone
    Other conditions: Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor
    View official trial listing →
  • Status unknown NCT NCT05019794

    Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

    Not yet reported LianBio LLC 80 participants Est. completion 2023-12-30 17 sites Stand-alone
    Other conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
    View official trial listing →
  • Enrolling by invitation NCT NCT05145010

    Extension Study of Infigratinib in Children With Achondroplasia (ACH)

    Not yet reported QED Therapeutics, a BridgeBio company 325 participants Est. completion 2032-02-01 31 sites Stand-alone
    Other conditions: Achondroplasia
    View official trial listing →
  • Withdrawn NCT NCT05222165

    Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

    Not yet reported, Not yet reported Helsinn Healthcare SA Est. completion 2022-12-16 10 sites Stand-alone
    Other conditions: Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
    View official trial listing →
  • Withdrawn NCT NCT05510427

    Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-08-07 Stand-alone
    Other conditions: Cholangiocarcinoma, Liver Cancer
    View official trial listing →
  • Withdrawn NCT NCT05514912

    Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

    Not yet reported Emory University Est. completion 2027-06-23 Stand-alone
    Other conditions: Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
    View official trial listing →
  • Completed NCT NCT06164951

    A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

    Not yet reported QED Therapeutics, a BridgeBio company 114 participants Est. completion 2025-12-18 27 sites Stand-alone
    Other conditions: Achondroplasia
    View official trial listing →
  • Terminated NCT NCT06206278

    Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

    Not yet reported LianBio LLC 6 participants Est. completion 2024-05-31 30 sites Stand-alone
    Other conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Enrolling by invitation NCT NCT06873035

    An Interventional Study of Infigratinib in Children With Hypochondroplasia

    Not yet reported, Not yet reported QED Therapeutics, a BridgeBio company 24 participants Est. completion 2027-01 24 sites Stand-alone
    Other conditions: Hypochondroplasia
    View official trial listing →
  • Active, not recruiting NCT NCT06926491

    Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）

    Not yet reported Kyowa Kirin Co., Ltd. 13 participants Est. completion 2031-05-31 9 sites
    Other conditions: Achondroplasia
    View official trial listing →
  • Enrolling by invitation NCT NCT07393373

    Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

    Not yet reported QED Therapeutics, a BridgeBio company 135 participants Est. completion 2036-05-31 24 sites Stand-alone
    Other conditions: Hypochondroplasia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.